BioVersys AG

BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on developing novel antibacterials for life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed to overcome resistance, block virulence and affect the pathogenesis of harmful bacteria. This enables BioVersys to address the unmet medical need for new treatments against life-threatening bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced programs address nosocomial infections of A. baumannii (BV100, Phase 2), and tuberculosis (alpibectir, Phase 2a, in collaboration with GSK and the University of Lille, France)